Loughborough University The Centre for Biological Engineering Doc Ref: FS008.1 : HTA-PR-FORM/007 Acquisition and Receipt of Biological Materials Version N°: 1.0 Issue Date:

ARF No: CBE/ARF/000 😮 🕽

PART A: To be completed by the	Receiver (a separate	form must be o	ompleted for	each sample	type)				
A1. Details of Sample/Specimen									
Type/ID: (eg primary cell, cell line, tissu fluid, excreta, biological agent)	Primary c	Primary cell							
Format / Quantity: (eg vials, slides, e	4 vials								
Tissue site/Organ source:	Normal Human Cor	Normal Human Cord Blood CD34/CD133+ Cells, Cryopreserved, Single Donor, 1 million cells/vial							
Batch N°:	HUCB041	HUCB041924A							
Is the sample/specimen considered to be Relevant Material under the Human Tissue Act (HTA)?									
Is the material obtained from an HTA licenced Tissue Bank with REC approval for generic research use?									
Is the material obtained for storage and use under a project specific NHS REC approval?									
Is the material licensable under the HTA? Indicate source below:									
☐ HTA licensed organisation ☑ C	Commercial Supplier	☐ Imported (fro	om outside Eng	land, Wales	or N.Ireland)				
If Yes, list lot numbers (or other identifier) & the corresponding assigned unique sample ID	Lot N°:	Lot N°: HUCB041924A			Assigned Unique ID (Procuro): S00387214,S00387215,S00387216, S00387217				
If Yes, provide Project Ref N°:	CBE BRA	CBE BRA 209							
If Yes, provide the name of the P	l: Alexandra	Alexandra Stolzing							
A2. Details of Receipt									
Date/Time of receipt	Date	09.01.2025		Time:	11am				
ID of Receiver	Name:	Yu Xiang		Dept:	CBE				
ID of Supplier/Provider	Name:	Zenbio		Country:	USA				
PART B: To be completed by the	Receiver					WEIGHT OF			
B1. Inspection and Quarantine									
Has a biological risk assessment for the use of this material been approved?		☑Yes □No		Ref Number: CBE BRA 209					
Physical integrity of the material(s) acceptable?		□Yes □No	If No, describ	ibe action taken					
Quantity received correct?		☑Yes □No	If No, describ	f No, describe action taken					
Labelling correct and legible?	☑Yes □No	If No, describe action taken							
Is the relevant documentation attached to this form?	C of A or equivalen	t evidence of	☑Yes □No □N/A						
	Agreements to enable transfer of material eg MTA, SLA		□Yes □No ☑N/A						
If No, add reference or details to ensure traceability	Details/evidence/assurance of		☑Yes □No □N/A						

	Other (describe)	. □Yes □No □N/A						
	Building/Room		The room with Nucleocounter 3000 🗸 🗸 🔾					
Temporary storage - Quarantine location (as applicable)	Storage Unit ID		Bank 6					
	Within storage unit location ID		Rack 5, Box D, 4-7					
	Date/Time of quarantine		09/01/2-15					
Submitted by:	Signature: Ju	Xiang	Date: 13/01/2025					
PART C: To be completed by the departmental Quality Manager								
C1. Quality Assurance Checks								
Has the sample/specimen been s	□Yes □No □N/A							
Has the donor been screened for	☐Yes ☐No ☐N/A							
Has the sample/specimen been s	□Yes □No □N/A							
Is there evidence that the supplied or other recognised certification?	□Yes □No □N/A							
For HTA licensable material, is the and use of the material under the	□Yes □No □N/A							
Is there sufficient evidence to sup	□Yes □No □N/A							
C2. Approval for release from quarantine								
Can the material be released from released for processing?	☑Yes ☐ No							
		☐ Accept as is, but with extra controls						
If No, provide recommendations for deposition of the material and the results of any action relating to non-conforming material.		☐ Rework or rep specified require	rocess to meet the ments					
		☐Test to meet s	pecified requirements	12.00				
relating to non-comorning mate	idi.	☐ Return to supplier/provider						
	,	□Disposal						
If Yes, provide details of storage lapplicable)		Building/Room		3				
	ocation (as	Storage Unit ID						
		Within storage unit location ID						
		Database Reference						
		Date/Time of tra	nsfer					
Approved by:		Signature:	all	Date: 13/1/25.				